
Lynparza
(olaparib)
(olaparib)
Capsules: 300 mg twice daily (2 pills twice daily).
Administer approximately every 12 hours with or without food. Swallow capsules whole; do not chew, dissolve, or open capsules.
Avoid grapefruit juice.
If you miss a dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up. If you miss more than one dose, talk to your doctor right away.
Males with female partners of reproductive potential or female partners who are pregnant should use effective contraception during treatment and for 3 months after the last Olaparib dose.
CBC w diff, CMP (baseline, monthly for 3 months, and every three months thereafter) and PSA as clinically indicated.
Lynparza is PARP inhibitor. Olaparib is a potent oral PARP inhibitor which induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired.
In layman’s terms: This medication is a PARP inhibitor. PARP is a protein that repairs DNA damage in cells, including cancer cells, so they can survive and grow. You are taking this medication because your cancer has certain HRR gene mutations and no longer responds to treatment that lowers testosterone. This medication helps to kill cancer cells by preventing PARP from repairing their DNA.
Lynparza (Olaparib) is approved for patients with metastatic CRPC who have failed xtandi or zytiga (PSA and radiologic) and who have evidence of a BRCA1, BRCA2, ATM, and/or 12 other mutations confirmed on genetic profiling.
Store at room temperature in the original bottle to protect from moisture.
Be sure to let your other prescribers know that you are taking this medication. This drug may interact with other drugs prescribed.
Notify MD of any new or worrisome side effects.